


Committee on Energy and Commerce
U.S. House of Representatives
 Witness Disclosure Requirement - "Truth in Testimony"
 Required by House Rule XI, Clause 2(g)

1. Your Name: Joshua M. Sharfstein		
2. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes X	No
3. Are you testifying on behalf of an entity that is not a government entity?	Yes	No X
4. Other than yourself, please list which entity or entities you are representing: State of Maryland		
5. Please list any Federal grants or contracts (including subgrants or subcontracts) that <u>you or the entity you represent have received</u> on or after October 1, 2009: The federal government provides many grants and contracts to states.		
6. If your answer to the question in item 3 in this form is "yes," please describe your position or representational capacity with the entity or entities you are representing: I am the Secretary of the Maryland Department of Health and Mental Hygiene. I am also chair of the Board of the Maryland Health Benefit Exchange.		
7. If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?	Yes	No X
8. If the answer to the question in item 3 is "yes," please list any Federal grants or contracts (including subgrants or subcontracts) that were received by the entities listed under the question in item 4 on or after October 1, 2009, that exceed 10 percent of the revenue of the entities in the year received, including the source and amount of each grant or contract to be listed:		
9. Please attach your curriculum vitae to your completed disclosure form. Attached		

Signature: _____



Date: 12/11/12

Joshua M. Sharfstein, M.D.

EMPLOYMENT

Maryland Department of Health and Mental Hygiene **January 2011 - Present**
Secretary

Gubernatorial appointment to lead the health department for the State of Maryland and chair the board of the Maryland Health Benefit Exchange.

U.S. Food and Drug Administration **March 2009 – January 2011**
Principal Deputy Commissioner

Presidential appointment to second-ranking position at the U.S. Food and Drug Administration. Led agency efforts on FDA-Track and the Transparency Task Force.

Baltimore City **December 2005-March 2009**
Commissioner of Health

Mayoral appointment to lead the oldest, continuously operating health department in the United States.

Governing Magazine Public Official of the Year 2008

4 Model Practice Awards to Health Department and affiliated agencies for Projects from the National Association of County and City Health Officials (2006-2009)

Government Reform Committee, U.S. House of Representatives **July 2001-Dec. 2005**
Minority Professional Staff and Health Policy Advisor

For Congressman Henry A. Waxman. Responsible for oversight and legislative projects on a variety of public health topics.

EDUCATION

Children's Hospital and Boston Medical Center

Fellowship in General Academic Pediatrics at Boston University, 2001.

Residency training in Pediatrics, 1999. Selected for Alpha Omega Alpha.

Harvard Medical School

M.D., 1996

Rose Seegal Award for Research

Community Service Award

Robert H. Ebert Prize in Primary Care

Harvard College

A.B. 1991 *summa cum laude*

Phi Beta Kappa

Thomas Temple Hoopes Prize

Frederick Sheldon Traveling Fellowship

PROFESSIONAL ACTIVITIES

Public Health Reports Contributing Editor, <i>Local Acts</i>	2007-2009
Institute of Medicine Member, Board on Population Health and Public Health Practice	2007-2009
Leadership for Healthy Communities Advisory Board member	2007-2009
Journal of the American Medical Association Editorial Board Member	2011-

PEDIATRICS

Medical Licensure and Board Certification Massachusetts Medical License 1997-2001 Board Certification in Pediatrics 1999, renewal 2006 Maryland Medical License, 2001-present District of Columbia Medical License, 2001-present	
Professional Memberships Fellow, American Academy of Pediatrics, 2001-present	
Children's National Medical Center Fast Track Physician, Emergency Department	2002-2005
Mount Washington Pediatric Hospital Adjuvant staff	2002-2005
Latino Clinic, Boston Medical Center Primary Care Pediatric Resident and Pediatrician	1996-2001
Dimock Street Community Health Center Primary Care Pediatric Resident	1997-1999

OTHER EXPERIENCE

- World Health Organization** **January-August 2000**
Researcher/Writer
Contributed to WHO report *Tobacco Company Strategies to Undermine Tobacco Control Activities at the World Health Organization*.
- Massachusetts Department of Public Health** **July 1999-June 2000**
Fellow (Part-time)
Co-author of papers on newborn screening policy and smoking in Chinatown.
- Docs4Kids Project** **Jan. 1997-June 1999**
Co-founder and Co-director
Organized national research and advocacy project on housing conditions and child health.
- U.S. Food and Drug Administration** **Spring 1996**
Intern, Office of the Commissioner
Drafted and edited portions of final jurisdictional analysis to tobacco rule.
- Public Citizen Health Research Group** **April-August 1992**
Researcher
- Project HOPE and Clinica de Pavas** **June 1991-April 1992**
Volunteer
Contributed to community-based projects in Xela, Guatemala and San Jose, Costa Rica.

PEER-REVIEWED SCIENTIFIC PUBLICATIONS

1. **Sharfstein J** and Sharfstein SS. Campaign contributions from the American Medical Political Action Committee to members of Congress: For or against the public health? *New England Journal of Medicine*.1994; 330: 32–37. Correction: 332:1450.
2. **Sharfstein J** and Wise P. Inadequate hepatitis B vaccination of adolescents and adults at an urban community health center. *Journal of the National Medical Association* 1997; 89:86–92.
3. **Sharfstein J**. Tackling tobacco or limiting malpractice awards? The campaign contribution priorities of the American Medical Association in the 1996 U.S. Congressional elections. *American Journal of Public Health* 1998; 88: 1233-1236.
4. **Sharfstein J**. Blowing smoke: How cigarette manufacturers argued that nicotine is not addictive. *Tobacco Control* 1999;8:210-213.
5. **Sharfstein J**, Sandel M, Kahn R, Bauchner H. Is child health at risk while families wait for housing vouchers? *American Journal of Public Health* 2001; 91:1191-2.
6. Bauchner H, **Sharfstein J**. Failure to report ethical approval in child health research: review of published papers. *British Medical Journal* 2001;323:318-9.

7. Atkinson KA, Zuckerman B, **Sharfstein J**, Levin D, Blatt R, Koh H. A public health response to emerging technology: expansion of the Massachusetts newborn screening program. *Public Health Reports* 2001; 116:122-31.
8. Averbach AR, Lam D, Lam LP, **Sharfstein J**, Cohen B, Koh H. Smoking behaviours and attitudes among male restaurant workers in Boston's Chinatown: a pilot study. *Tobacco Control* 2002;11 Suppl 2: ii34-7
9. O'Keefe, G, Veale L, North M, Goetzinger K, Stewart J, **Sharfstein J**. A public health response to the implementation of Medicare Part D. *Public Health Reports* 2007; 122(1)101-4.
10. Schnitzer, MI, Kaplin DB, Keane VA, Zuckerman B, **Sharfstein J**. Giving literacy a shot in the arm. *Public Health Reports* 2008; 123(4): 523-6.

SELECTED OTHER PUBLICATIONS

1. Torrey EF, Stieber J, Ezekiel R, Wolfe S, **Sharfstein J**, Noble J and Flynn L. *Criminalizing the Seriously Mentally Ill: The Abuse of Jails as Mental Hospitals*. Washington D.C.: Public Citizen and the National Alliance for the Mentally Ill, 1992.
2. **Sharfstein J** and Gupta A. Confidentiality of radiologic images. Letter. *Radiology* 1995: 873-4.
3. **Sharfstein J**. Pfizer Night at Boston Billiards. Letter. *New England Journal of Medicine* 1997; 337(2):134.
4. **Sharfstein, J** and Sandel M. Editors. *Not Safe at Home: How America's Housing Crisis Threatens the Health of Its Children*. Boston: Boston Medical Center Department of Pediatrics, 1998. Reprinted in *Health Policy & Child Health* 1998; 5(1):1-6. and *Journal of Housing and Community Development* 1998;55(4): 14-24.
5. **Sharfstein J**, Jeffery P and Agrawal D. A case of phenytoin toxicity. *Pediatrics* 1998 Nov;102(5):1223.
6. **Sharfstein J**, Babl F. Cat scratch disease without cat scratch. *Infectious Diseases in Children* 1999; August: 58.
7. **Sharfstein J**. Folic Acid Antagonists during pregnancy and risk of birth defects. Letter. *New England Journal of Medicine* 2001; 344:933.
8. **Sharfstein J**. Unhealthy Partnership. *The American Prospect*. January 1-15, 2001: 24-28.
9. Story E and **Sharfstein J**. Needed: 'MCAS' for children's mental health care. *Boston Globe*. 15 April 2001: D4.
10. Phillips F and **Sharfstein J**. A Medicaid provision to repeal. *Washington Post*. 4 March 2007: B8.
11. **Sharfstein J**, North M, Serwint JR. Over the counter but no longer under the radar—pediatric cough and cold medications. *New England Journal of Medicine* 2007; 357: 2321-4.
12. Hamburg MA and **Sharfstein J**. The FDA as a Public Health Agency. *New England Journal of Medicine* 2009; 360: 2493-2495.

13. Deyton L, **Sharfstein J**, and Hamburg MA. Tobacco Product Regulation – A Public Health Approach. *New England Journal of Medicine* 2010; 362: 1753-1756.
14. Asamoah A and **Sharfstein J**. Transparency at the Food and Drug Administration. *New England Journal of Medicine* 2010; 362: 2341-2343.
15. Woodcock A, **Sharfstein J**, and Hamburg MA. Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration. *New England Journal of Medicine* 2010; 363: 1489-1491.
16. **Sharfstein J**. The FDA--A Misunderstood Agency. *Journal of the American Medical Association*. 2011;306(11):1250-1.
17. **Sharfstein J**. In sickness and in health: Physicians as captains of the ship. *Maryland Medicine*. 2011;12(3):13-4.
18. Bazinsky KR, Herrera L, **Sharfstein J**. Toward innovative models of health care and financing: matchmaking in Maryland. *Journal of the American Medical Association*. 2012;307(12):1261-2.
19. Emanuel E, Tanden N, Altman S, Armstrong S, Berwick D, de Brantes F, Calsyn M, Chernew M, Colmers J, Cutler D, Daschle T, Egerman P, Kocher B, Milstein A, Oshima Lee E, Podesta JD, Reinhardt U, Rosenthal M, **Sharfstein J**, Shortell S, Stern A, Orszag PR, Spiro T. A systemic approach to containing health care spending. *New England Journal of Medicine*. 2012;367(10):949-54. Epub 2012 Aug 1.
20. Steinbrook R, **Sharfstein J**. The FDA Safety and Innovation Act. *Journal of the American Medical Association*. 2012;308(14):1437-8.
21. **Sharfstein J**, Herrera L, Milligan C. Health care reform: caring about costs, too. *Baltimore Sun*. 27 September 2012.
22. Wilson LE, Blythe D, **Sharfstein J**. Fungal Meningitis From Injection of Contaminated Steroids: A Compounding Problem. *Journal of the American Medical Association*. 2012 Oct 26:1-2.